Similar Search Results

Group living for elderly patients with dementia -- A cost analysis

Svensson, Marianne; Edebalk, Per Gunnar; Persson, Ulf - In: Health Policy 38 (1996) 2, pp. 83-100

Persistent link: https://www.econbiz.de/10005516183

The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden

Willis, Michael; Svensson, Marianne; Löthgren, Mickael; … - In: The European Journal of Health Economics 11 (2010) 6, pp. 585-594

Persistent link: https://www.econbiz.de/10008775862

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 10 (2012) 4, pp. 217-225

Sweden has experienced a national value-based pricing (VBP) system for innovative outpatient drugs operated by the Pharmaceutical Benefits Board — LFN (now called the Dental and Pharmaceutical Benefits agency — TLV) since 2002. VBP has the character of a monopoly system, leading to...

Persistent link: https://www.econbiz.de/10011000768

Authors’ Reply to Godman and Gustafsson: “A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing”

Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 11 (2013) 1, pp. 83-84

Persistent link: https://www.econbiz.de/10011000861

A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden

Persson, Ulf; Willis, Michael; Ödegaard, Knut - In: The European Journal of Health Economics 11 (2010) 2, pp. 195-203

Persistent link: https://www.econbiz.de/10009404141

Reimbursement and clinical guidance for pharmaceuticals in Sweden

Anell, Anders; Persson, Ulf - In: The European Journal of Health Economics 6 (2005) 3, pp. 274-279

Persistent link: https://www.econbiz.de/10009404270

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 10 (2012) 4, pp. 217-225

Sweden has experienced a national value-based pricing (VBP) system for innovative outpatient drugs operated by the Pharmaceutical Benefits Board - LFN (now called the Dental and Pharmaceutical Benefits agency - TLV) since 2002. VBP has the character of a monopoly system, leading to reimbursement...

Persistent link: https://www.econbiz.de/10010552620

Cost Effectiveness of Becaplermin in the Treatment of Diabetic Foot Ulcers in Four European Countries

Ghatnekar, Ola; Persson, Ulf; Willis, Michael; … - In: PharmacoEconomics 19 (2001) 7, pp. 767-778

Objective: The primary objective of this study was to estimate the cost effectiveness of treating diabetic foot ulcers with becaplermin (Regranex(R)) plus good wound care (GWC) compared with GWC alone in a variety of European healthcare settings. A secondary objective was to analyse the effect...

Persistent link: https://www.econbiz.de/10005449166

Relative risk values of non-fatal traffic injuries - a comparison between contingent valuation, risk-risk trade off and standard gamble methods

Persson, Ulf; Trawén, Anna; Norinder, Anna; Hjalte, Krister - In: Swiss Journal of Economics and Statistics (SJES) 137 (2001) I, pp. 117-128

None

Persistent link: https://www.econbiz.de/10005581065

Acquisition cost of dispensed drugs in individuals with multiple medications--A register-based study in Sweden

Hovstadius, Bo; Åstrand, Bengt; Persson, Ulf; … - In: Health Policy 101 (2011) 2, pp. 153-161

Objectives To analyse the acquisition cost of dispensed prescription drugs for individuals with multiple medications in a national population.Methods We collected and analysed individual based data regarding the acquisition cost of dispensed prescription drugs for all individuals with five or...

Persistent link: https://www.econbiz.de/10009146619